索托拉西布新

参考资料仅供科学研究，不可用于个人用途。

货号：BCP33368CAS号：2296729-00-3纯度：98%

规格	价格(CNY)	是否现货	购买咨询
100.00 mg	￥260.00	In-stock	购买咨询
250.00 mg	￥480.00	In-stock	购买咨询
1.00 g	￥1300.00	In-stock	购买咨询

在线咨询

大批量询价

全国免运费！免费咨询：400-099-8200 或手机联系：13472751340

* 必填项

请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。

* Required Fields.

Please complete the form below and we will contact you shortly.

* Required Fields.

Please complete the form below and we will contact you shortly.

CAS号	2296729-00-3	货号	BCP33368
关联产品	2252403-56-6（AMG510 racemate(外消旋体)）
中文名	索托拉西布
英文名	Sotorasib
中文别名	索托拉司;AMG-510单一构型;AMG510单一构型;
英文别名	AMG510;AMG 510;AMG-510;
SMILES	O=C1N(C2=C(C)C=CN=C2C(C)C)C3=NC(C4=C(O)C=CC=C4F)=C(F)C=C3C(N5[C@@H](C)CN(C(C=C)=O)CC5)=N1
化学名称
分子式	C30H30F2N6O3	分子量	560.61
纯度	98%	配送	惯例下常温包邮
产品描述	Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer. This mutation makes up >50% of all KRAS mutations. Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s. It is the first experimental KRAS inhibitor. The drug [MRTX849] is also currently being developed and has the same target. Sotorasib was granted FDA approval on May 28, 2021, followed by the European Commission's approval on January 10, 2022.

索托拉西布 新